Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6738 and Olaparib in Relapsed SCLC
NCT03428607Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Oct 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ceralasertib in small cell lung cancer (SCLC), sponsored by Samsung Medical Center. Started Oct 2018; status: completed.
02
Drugs
ceralasertib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03428607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03428607.